Plain-English translation of NCT05791448 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a new medication called AU409 in patients with advanced liver cancer or other cancers that have spread to the liver. The trial will gradually increase the dose to find the safest and most effective amount, and watch carefully for side effects. Researchers will also measure whether this treatment slows or shrinks tumors.
Currently, there are limited treatment options for advanced liver cancers and cancers that have spread to the liver, especially when standard therapies are no longer working. This trial is exploring whether this new medication could offer hope to patients with these difficult-to-treat cancers.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth as directed by the research team. Throughout the trial, you will have regular visits for blood tests and imaging scans (CT or MRI) to monitor how the medication is working and check for side effects. The study starts with small doses that are gradually increased in groups of patients to find the safest dose. Some participants may have a liver biopsy to help researchers understand how the medication works in tumor tissue.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States